Introduction & Objective: This post hoc analysis assessed the treatment effects of once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators across different age groups in adults with T2D.
Methods: Efficacy outcomes and hypoglycemia rates for icodec vs OD comparators across three age subgroups (<55, 55-64 and ≥65 years) were assessed, by trial, in insulin-naïve (ONWARDS 1, 3, 5) and insulin-treated (ONWARDS 2, 4) adults with T2D.
Results: There were no statistically significant treatment by subgroup interactions for change in A1C from baseline to planned end of treatment (EOT) (Figure). A larger reduction in A1C with icodec was seen across age subgroups in ONWARDS 1-5, except for individuals ≥ 65 years in ONWARDS 4, where the opposite trend was seen. Overall, rates of clinically significant and severe hypoglycemic episodes were low in both treatment arms across age subgroups. In ONWARDS 1-5, the proportions of individuals achieving A1C <7% without clinically significant or severe hypoglycemic episodes at planned EOT were higher for icodec vs OD comparators irrespective of age, except for individuals < 55 and ≥ 65 years in ONWARDS 4; no statistically significant difference was seen in the treatment by subgroup interaction across different age subgroups.
Conclusion: Overall, efficacy and hypoglycemia outcomes were consistent for icodec vs OD comparators irrespective of age.
A.G.D. Vianna: Board Member; Abbott, Lilly Diabetes, Novo Nordisk, Medtronic. Speaker's Bureau; AstraZeneca, Novo Nordisk. Research Support; Novo Nordisk, Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Research Support; Servier Laboratories. C. Desouza: Advisory Panel; Novo Nordisk, Bayer Inc., Madrigal Pharmaceuticals, Inc. Other Relationship; ADA/ACC Diabetes by Heart Program. Advisory Panel; Asahi Kasei. C. Laugesen: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. M. Fragão Marques: None. P. Nielsen: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. S.S. Shaikh: None. I. Lingvay: Consultant; Altimmune, Astra Zeneca, Bayer, Biomea, Boehringer-Ingelheim, Carmot, Cytoki Pharma, Eli Lilly, Intercept, Janssen/J&J, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Sanofi. Research Support; NovoNordisk, Sanofi, Mylan, Boehringer-Ingelheim. Consultant; TERNS Pharma, The Comm Group, Valeritas, WebMD, and Zealand Pharma.
Novo Nordisk A/S
